At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 353 enrolled
Drug / intervention
Placebo Control +3 moredrug
Likely dose
ELND005 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Placebo Control and ELND005 for Alzheimer Disease. Completed, enrolled 353 participants across 62 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionMay 2010
TodayJul 2026
First PostedDec 6, 2007
Enrollment StartDec 1, 2007
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.6 years ago
Interventions
Placebo Controldrug
ELND005 matched placebo capsules for oral administration, bid for 78 weeks
ELND005drug
ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
ELND005drug
ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
ELND005drug
ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks